Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

This study is testing a new drug called EMB-01 in people with colorectal cancer that has come back or spread. The cancer must originate from the left side of the colon or rectum and not be removable by surgery. **You may be eligible if...** - You are 18 or older - You have confirmed advanced or metastatic left-sided colorectal cancer with at least one measurable tumor - You have already tried at least one or two standard chemotherapy regimens (including fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab) and they stopped working - You are in generally good physical condition (ECOG score 0 or 1) - You can provide a tumor tissue sample **You may NOT be eligible if...** - Your tumor has certain genetic mutations (KRAS, NRAS, BRAF V600E, HER2, RET, or NTRK) - You have active brain metastases with symptoms - You have previously had serious skin reactions (Stevens-Johnson syndrome) or had prior combined anti-EGFR/cMET therapy - Your life expectancy is less than 3 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.